JP2018536659A5 - 白内障および老視の抑制に用いられるpegを含有する二官能性分子を含む眼科用組成物 - Google Patents

白内障および老視の抑制に用いられるpegを含有する二官能性分子を含む眼科用組成物 Download PDF

Info

Publication number
JP2018536659A5
JP2018536659A5 JP2018524251A JP2018524251A JP2018536659A5 JP 2018536659 A5 JP2018536659 A5 JP 2018536659A5 JP 2018524251 A JP2018524251 A JP 2018524251A JP 2018524251 A JP2018524251 A JP 2018524251A JP 2018536659 A5 JP2018536659 A5 JP 2018536659A5
Authority
JP
Japan
Prior art keywords
ophthalmic
ophthalmic composition
composition
presbyopia
ophthalmic compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018524251A
Other languages
English (en)
Other versions
JP2018536659A (ja
JP6794444B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/061490 external-priority patent/WO2017083619A1/en
Publication of JP2018536659A publication Critical patent/JP2018536659A/ja
Publication of JP2018536659A5 publication Critical patent/JP2018536659A5/ja
Application granted granted Critical
Publication of JP6794444B2 publication Critical patent/JP6794444B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (9)

  1. 二官能性分子を含む眼科用組成物であって、前記二官能性分子は、

    ある、眼科用組成物。
  2. 前記眼科用組成物が点眼剤である、請求項に記載の眼科用組成物
  3. 前記眼科用組成物は、眼科用液剤、眼科用懸濁剤、眼科用軟膏剤、スプレー剤または眼科用ゲル剤の形態である、請求項に記載の眼科用組成物
  4. 前記眼科用組成物は、緩衝剤、等張化剤、可溶化剤、防腐剤、増粘剤、キレート剤、抗酸化剤、抗生物質、糖およびpH調節剤またはそれらの組み合わせを含む、請求項に記載の眼科用組成物
  5. 前記眼科用組成物は眼科用デバイス内に含まれている、請求項に記載の眼科用組成物
  6. 前記眼科用デバイスは、コンタクトレンズまたは涙点プラグの形態にある、請求項に記載の眼科用組成物
  7. 前記眼科用組成物は、徐放性組成物である、請求項に記載の眼科用組成物
  8. 請求項1〜7のいずれか一項に記載の眼科用組成物であって、白内障形成、老視または眼の水晶体の加齢に関連する変性の進行を抑制または後退させる方法において使用するための眼科用組成物。
  9. 前記眼科用組成物は、前記方法において、点眼、噴霧、注入、イオントフォレシスまたは超音波増強によって投与されるものである、請求項に記載の眼科用組成物
JP2018524251A 2015-11-13 2016-11-11 白内障および老視の抑制に用いられるpegを含有する二官能性分子を含む眼科用組成物 Active JP6794444B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562254863P 2015-11-13 2015-11-13
US62/254,863 2015-11-13
PCT/US2016/061490 WO2017083619A1 (en) 2015-11-13 2016-11-11 Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia

Publications (3)

Publication Number Publication Date
JP2018536659A JP2018536659A (ja) 2018-12-13
JP2018536659A5 true JP2018536659A5 (ja) 2019-12-19
JP6794444B2 JP6794444B2 (ja) 2020-12-02

Family

ID=57421950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018524251A Active JP6794444B2 (ja) 2015-11-13 2016-11-11 白内障および老視の抑制に用いられるpegを含有する二官能性分子を含む眼科用組成物

Country Status (18)

Country Link
US (1) US10736863B2 (ja)
EP (1) EP3373921B1 (ja)
JP (1) JP6794444B2 (ja)
KR (1) KR20180083378A (ja)
CN (1) CN108348494A (ja)
AU (1) AU2016354479B2 (ja)
CA (1) CA3004585A1 (ja)
CL (1) CL2018001282A1 (ja)
CR (1) CR20180294A (ja)
EA (1) EA035402B1 (ja)
ES (1) ES2745291T3 (ja)
IL (1) IL259027B (ja)
MX (1) MX2018005903A (ja)
PE (1) PE20181070A1 (ja)
SA (1) SA518391553B1 (ja)
SG (1) SG11201803606XA (ja)
WO (1) WO2017083619A1 (ja)
ZA (1) ZA201802978B (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2727293T3 (es) 2013-03-14 2019-10-15 Univ Massachusetts Métodos de inhibición de cataratas y presbicia
EA035402B1 (ru) 2015-11-13 2020-06-08 Зе Юниверсити Оф Массачусеттс Бифункциональные молекулы, содержащие полиэтиленгликоль, для подавления катаракт и пресбиопии
US10220012B2 (en) 2016-06-03 2019-03-05 Joerg H. KRUMEICH Solution for ophthalmology
TWI798452B (zh) * 2019-06-17 2023-04-11 晶碩光學股份有限公司 隱形眼鏡產品
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526789A (en) 1980-02-29 1985-07-02 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation
US4351826A (en) 1980-02-29 1982-09-28 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using acrylamides
US4665089A (en) 1985-03-21 1987-05-12 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using protein modification reagents
US4620979A (en) 1985-08-02 1986-11-04 Schachar Ronald A Ophthalmological irrigating solution containing ascorbate
US4771036A (en) 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
CA1269327A (en) 1986-04-24 1990-05-22 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using protein modification reagents
US5055291A (en) 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4808182A (en) 1986-11-26 1989-02-28 Nestle, S.A. Deswelled, hydrogel intraocular lenses
US5091421A (en) 1987-06-04 1992-02-25 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors
US5338545A (en) 1987-06-04 1994-08-16 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
US5614587A (en) 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
DE3906311A1 (de) 1989-02-28 1990-08-30 Adatomed Pharma & Med Behandlungsystem zur verhinderung von nachstarbildung nach einer kataraktoperation
WO1992000748A1 (en) 1990-07-06 1992-01-23 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
ATE138914T1 (de) 1990-12-10 1996-06-15 Bio Physio Pharmaceutical Rese Indeno-d-pyrimidonverbindungen zur verwendung in der medizin
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
PL171704B1 (pl) 1992-05-20 1997-06-30 Senju Pharma Co Sposób wytwarzania srodka farmaceutycznego do leczenia lub profilaktyki zacmy PL
US5375611A (en) 1993-01-26 1994-12-27 Pharmacia Ab Method for preventing secondary cataract
CN1045383C (zh) 1993-04-07 1999-10-06 王慧康 用于治疗老年性白内障的药物组合物
US5663304A (en) 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
WO1995013827A1 (en) 1993-11-19 1995-05-26 The University Of Sydney A method for preventing or controlling cataract
US5516534A (en) 1993-11-26 1996-05-14 Rensselaer Polytechnic Institute Composition and method for reducing structural defects
US5591773A (en) 1994-03-14 1997-01-07 The Trustees Of Columbia University In The City Of New York Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters
WO1995031223A1 (fr) 1994-05-13 1995-11-23 Kuraray Co., Ltd. Gel polymere a usage medical
EP0733918B1 (en) 1995-03-24 2003-07-30 Ocular Research of Boston, Inc. Hydrogel lens pre-coated with lipid layer
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JP3599848B2 (ja) 1995-09-11 2004-12-08 株式会社メニコン 含水性軟質眼用レンズ用材料、それからなる含水性軟質眼用レンズ用成形体、ならびにそれからなる含水性軟質眼用レンズおよびその製法
EP0781777A1 (en) 1995-12-28 1997-07-02 Menicon Co., Ltd. Silicon-containing compound and ocular lens material
EP0816398B1 (en) 1996-06-28 2002-08-14 Ube Industries, Ltd. Process for producing polybutadiene
US5817630A (en) 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
JPH10339857A (ja) 1997-06-05 1998-12-22 Menicon Co Ltd 薬剤徐放性コンタクトレンズの製法およびそれによってえられた薬剤徐放性コンタクトレンズ
US6015787A (en) 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
US6291466B1 (en) 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
EP1149909A1 (en) 2000-04-28 2001-10-31 Boehringer Mannheim Gmbh Methods for regulating protein conformation using molecular chaperones
US6103756A (en) 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
CA2389917A1 (en) 1999-11-04 2001-05-10 Kazunori Kataoka A polymer micelle as monolayer or layer-laminated surface
US6835394B1 (en) 1999-12-14 2004-12-28 The Trustees Of The University Of Pennsylvania Polymersomes and related encapsulating membranes
US7977385B2 (en) 2000-03-02 2011-07-12 Numoda Biotechnologies, Inc. Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
CN1436083A (zh) * 2000-05-31 2003-08-13 塞鲁斯公司 制备病原体灭活的低免疫原性红细胞溶液
US7833977B2 (en) 2000-12-15 2010-11-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of L-Carnitine as stabilizing agent of proteins
US6958224B2 (en) 2001-03-28 2005-10-25 Council Of Scientific And Industrial Research Chimeric protein α BNAC crystallin with extraordinarily high chaperone-like activity and a method related to the use thereof
US20030020870A1 (en) 2001-06-27 2003-01-30 Zms, Llc Biomedical molding materials from semi-solid precursors
JP4838968B2 (ja) * 2001-09-28 2011-12-14 参天製薬株式会社 薬物−ポリエチレングリコール結合体を含有する眼組織内注入剤
KR20110025239A (ko) 2001-09-28 2011-03-09 산텐 세이야꾸 가부시키가이샤 약물-폴리에틸렌글리콜 결합체를 함유하는 안조직 내 주입제
US20050260259A1 (en) 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US20030223957A1 (en) 2002-04-10 2003-12-04 Schwartz Daniel M. Biodegradable PEG based polymer formulations in ocular applications
US6924154B2 (en) 2002-08-20 2005-08-02 Quest Diagnostics Investments Incorporated Hydrophilic chemilumescent acridinium labeling reagents
JP2004161731A (ja) 2002-09-25 2004-06-10 Nof Corp 生体関連物質用固定化剤
DE602004024041D1 (de) 2003-03-05 2009-12-24 Halozyme Inc Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen
CN1621091A (zh) 2003-11-28 2005-06-01 付经国 聚乙二醇化轮状病毒体肠靶向制剂及其合成方法
WO2005076998A2 (en) 2004-02-05 2005-08-25 Intradigm Corporation Rnai therapeutics for treatment of eye neovascularization diseases
WO2005110375A1 (en) 2004-05-08 2005-11-24 Paul Edward L Jr Nutritional supplement for treatment of ocular diseases
WO2005117987A1 (en) 2004-06-01 2005-12-15 Glazier Alan N Antibody conjugates targeting to ocular proteins
EP2626368B1 (en) 2004-07-19 2016-12-21 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US6945971B1 (en) 2004-07-19 2005-09-20 Gwon Arlene E Controlled ocular lens regeneration
US20080227700A1 (en) 2004-11-04 2008-09-18 Ghosh Joy G Compositions and Methods for Treatment of Protein Misfolding and Protein Aggregation Diseases
US7741311B2 (en) 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
CN1660920A (zh) 2005-02-01 2005-08-31 华东理工大学 末端连接ω-氨基酸的聚乙二醇酸或活性酯及制法和应用
US20060252107A1 (en) 2005-02-22 2006-11-09 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
DE102005041570A1 (de) 2005-09-01 2007-03-22 Celares Gmbh Hoch verzweigte Reagenzien zur Modifaktion von Biopharmazeutika, deren Herstellung und Anwendung
US7832875B2 (en) 2005-09-29 2010-11-16 Virtek Vision International Inc. Modulated diode pumped microchip laser projector
US20080094573A1 (en) 2006-04-04 2008-04-24 Vermette Patrick Surface-modified materials, such as contact lenses, methods and kits for their preparation, and uses thereof
US20070275098A1 (en) 2006-05-19 2007-11-29 T.R.P. Company, Inc, A Nevada Corporation Formulation and methodology for the treatment for eye impairment symptoms
WO2008145721A2 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
WO2009029991A1 (en) 2007-09-07 2009-03-12 Meat & Livestock Australia Limited Agents with angiogenic and wound healing activity
CN103120690A (zh) 2007-10-19 2013-05-29 株式会社·R-技术上野 用于治疗白内障的药物组合物
KR20100000203A (ko) 2008-06-24 2010-01-06 인하대학교 산학협력단 금나노입자를 이용한 표적지향형 항암약물전달체
BRPI0913653A2 (pt) 2008-06-30 2015-10-20 Johnson & Johnson Vision Care métodos e dispositivos oftálmicos usados no tratamento de alergias oculares
BRPI0823084B1 (pt) * 2008-07-14 2019-07-16 Biocon Limited Método de síntese de uma mistura de oligômeros substancialmente monodispersa
WO2010065024A1 (en) 2008-12-05 2010-06-10 Kador Peter F Topical treatment of cataracts in dogs
WO2010130638A1 (en) 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
WO2011075430A1 (en) * 2009-12-14 2011-06-23 University Of Massachusetts Methods of inhibiting cataracts and presbyopia
WO2011133566A2 (en) 2010-04-19 2011-10-27 University Of Louisville Research Foundation, Inc. Repairing bruch's membrane with hydrogels
US9676871B2 (en) 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CN102172410B (zh) 2011-01-14 2013-08-07 华南理工大学 用于癌症诊断与治疗的靶向纳米粒传输系统的构建方法
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
CN103918055B (zh) 2011-03-31 2016-08-17 Dh科技发展私人贸易有限公司 用于校准质谱仪的组合物、方法和试剂盒
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
BR112013031039B1 (pt) * 2011-06-03 2020-04-28 3M Innovative Properties Co compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado
CN106146649B (zh) 2011-09-04 2020-09-01 株式会社糖锁工学研究所 附加糖链的多肽和含有该多肽的医药组合物
RU2014118642A (ru) 2011-10-12 2015-11-20 Асцендис Фарма Офтальмолоджи Дивижн А/С Предотвращение и лечение глазных нарушений
CN102579353B (zh) 2012-03-30 2013-12-04 吉林大学 叶酸靶向的抗癌药物peg修饰的脂质体及制备方法
JP6209791B2 (ja) * 2012-07-17 2017-10-11 リージェンツ オブ ザ ユニバーシティ オブ ミシガン 白内障を処置するためのα−クリスタリン凝集の阻害剤
AU2013328782C1 (en) 2012-10-11 2018-01-18 Ascendis Pharma Ophthalmology Division A/S VEGF neutralizing prodrugs for the treatment of ocular conditions
WO2014071132A1 (en) 2012-11-01 2014-05-08 The Johns Hopkins University Contact lens surface modification with hyaluronic acid (ha) binding peptide for ha accumulation and retention
ES2727293T3 (es) 2013-03-14 2019-10-15 Univ Massachusetts Métodos de inhibición de cataratas y presbicia
WO2014171842A1 (en) 2013-04-19 2014-10-23 Living Cell Technologies New Zealand Limited Biocompatible encapsulation system
CN113274506A (zh) 2013-12-05 2021-08-20 念·吴 聚合物-碳水化合物的缀合物的药物转递技术
EA035402B1 (ru) 2015-11-13 2020-06-08 Зе Юниверсити Оф Массачусеттс Бифункциональные молекулы, содержащие полиэтиленгликоль, для подавления катаракт и пресбиопии

Similar Documents

Publication Publication Date Title
JP2018536659A5 (ja) 白内障および老視の抑制に用いられるpegを含有する二官能性分子を含む眼科用組成物
MX2019007587A (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
JP2014139241A5 (ja)
WO2017158366A3 (en) Ophthalmic delivery device and ophthalmic drug compositions
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
MA40306A1 (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
EA201591176A1 (ru) Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном
PH12015502587A1 (en) Opthalmic nanoemulsion composition containing cyclosporine and method for preparing same
BR112017015230A2 (pt) método de determinação de um filtro para uma lente oftálmica e lente oftálmica compreendendo um filtro desta natureza
EA200700109A1 (ru) Способы лечения офтальмологических состояний (варианты)
WO2018033792A3 (en) Ophthalmic pharmaceutical compositions and uses relating thereto
MA47688A (fr) Compositions utiles dans le traitement de l'amyotrophie spinale
JP2013006877A5 (ja)
JP2020070301A5 (ja)
IL273531A (en) Ophthalmic preparations containing latanoprost for use in the treatment of eye diseases
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
SG11202008901WA (en) Ophthalmic compositions, and ocular uses thereof, of indigo carmine
CL2018001282A1 (es) Moléculas bifuncionales que contienen peg para su uso en la inhibición de cataratas y presbicia
BR112015023348A2 (pt) método de inibição ou reversão da progressão da formação de catarata, composição oftálmica, e, método de tratamento de uma doença relacionada ao dobramento de proteínas
WO2015094019A3 (ru) Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
SG11202106967QA (en) Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
JP2014210813A5 (ja)
MA39228A1 (fr) Compositions à utiliser pour le traitement d'états allergiques
JP2013513622A5 (ja)
TR201812013T4 (tr) Göz yikama bi̇leşi̇mleri̇.